Virtual Tour
Choose a tour below:
more
Client Profile
Thermalin Diabetes, Inc.
Based in Cleveland and built on technology developed by Dr. Michael A. Weiss at Case Western Reserve Medical School, Thermalin Diabetes, LLC is developing clinically-superior, second generation, insulin analogs for the rapidly-growing $12 billion insulin market. Themalin's patent pending compounds include rapid-, intermediate - and long-acting analogs. For more information, please contact Richard Berenson(rick@thermlin.com).
- CEO
- Richard Berenson
- Type of Business
- Biotech
- Number of Employees
- 7
- Recent Successes
- Closed a $2.85 million Series A investment round.
Latest News
- IschemiaCare Receives State Loan for Stroke Test January 20, 2012
- Biomarker test firm Cleveland HeartLab closes $18.4M investment August 22, 2011
- Wound therapy company SironRX closes $3.4M series A investment August 15, 2011
- Research Team Allies with ImageIQ to Improve Umbilical Cord Blood Stem Cell Characterization August 4, 2011
- ImageIQ Participates in a NASA Funded Musculoskeletal Research Study Aboard Space Shuttle Mission STS-135 July 8, 2011
- St. Joseph Health System Joins the Explorys Network June 20, 2011
- MIT Selects ImageIQ for Image Analysis and Software Engineering to Support Research Studies June 8, 2011
- Renovo on cutting edge of cure for MS June 3, 2011